However, sorafenib-alone or sorafenib + TGF-β1 treatment significantly reduced the tumor cell invasion capacity (P < 0.05; Figure 5(a) and (b)), suggesting that sorafenib was able to inhibit tumor cell invasion, especially the TGF-β1-enhanced ovarian cancer cell EMT. Here, TGFB1 is linked to ovarian cancer.